# OnCo record tivozanib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tivozanib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tivozanib" ;
  schema:name "Tivozanib"@en ;
  schema:description "Tivozanib is a VEGF-receptor pill that hits VEGFR1 to 3 with little off-target kinase activity, so it is better tolerated than other anti-angiogenic pills, though hypertension and fatigue remain common. It is approved for kidney cancer after two or more prior treatments, and its TiNivo-2 trial showed that restarting immunotherapy after failure adds nothing."@en ;
  schema:url <https://onco.cc/drugs/tivozanib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tivozanib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7810457> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tivozanib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (VEGFR)" ;
  schema:alternateName "Fotivda" ;
  onco:approval "US 2021: Relapsed/refractory advanced RCC after ≥2 prior systemic therapies", "EU 2017: EU first (Aug 2017)" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/aveo/> ;
  onco:trials <https://onco.cc/trials/tinivo-2/> .